{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:41:40Z","timestamp":1792086100663,"version":"4.4.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Escitalopram is metabolized by CYP2C19 to <jats:italic toggle=\"yes\">N<\/jats:italic>-desmethyl escitalopram and escitalopram propionic acid. The primary aims of this study were to investigate the impact of the CYP2C19 phenotype on metabolic ratios of escitalopram in vivo and propose a biomarker for the CYP2C19 phenotype in patients treated with escitalopram.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Median steady-state serum metabolite\/parent drug ratio of <jats:italic toggle=\"yes\">N<\/jats:italic>-desmethyl escitalopram and escitalopram propionic acid was investigated across CYP2C19 genotype-translated phenotype groups. The receiver operator characteristics method and the area-under-the-receiver-operator-characteristics curve was used to determine the best suited metabolic ratio for detecting CYP2C19 poor metabolizers (PMs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 441 patients were included in the study. The <jats:italic toggle=\"yes\">N<\/jats:italic>-desmethyl escitalopram\/escitalopram ratio was 67% and 44% lower in CYP2C19 PMs and intermediate metabolizers (IMs), respectively, than normal metabolizers. Furthermore, the ability of the ratio to predict CYP2C19 PMs was 92%. A metabolic ratio of &lt;0.24 was detected in 8 of 8 PMs in the study, indicating that it is a promising biomarker of reduced CYP2C19 activity. The escitalopram propionic acid\/escitalopram ratio was 77% and 48% lower in CYP2C19 PMs and IMs, respectively; however, the ability of the ratio to detect CYP2C19 PMs was only 87%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>These findings suggest that DECT\/ECT reflects CYP2C19 activity, and a metabolic ratio of &lt;0.24 strongly predicts CYP2C19 PM phenotype. The ratio could be a valuable alternative to genotyping in personalized dosing of escitalopram and possibly other CYP2C19 substrates. The escitalopram propionic acid\/escitalopram ratio was also associated with CYP2C19 activity; however, the ratio was inferior to the DECT\/ECT at predicting PMs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000991","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T05:01:08Z","timestamp":1668402068000},"page":"720-728","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers"],"prefix":"10.1097","volume":"44","author":[{"given":"Pari","family":"Faraj","sequence":"first","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Hermansen","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital;"},{"name":"Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Hole","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital;"},{"name":"Department of Life Sciences and Health, Oslo Metropolitan University, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/17425255.2014.863873","article-title":"Clinical pharmacology review of escitalopram for the treatment of depression","volume":"10","author":"Pastoor","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2147\/PPA.S22495","article-title":"Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability","volume":"6","author":"Kirino","year":"2012","journal-title":"Patient Prefer Adherence."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","article-title":"Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients","volume":"175","author":"Juki\u0107","year":"2018","journal-title":"Am J Psychiatry."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FPC.0b013e328340bc5a","article-title":"CYP2C19 variation and citalopram response","volume":"21","author":"Mrazek","year":"2011","journal-title":"Pharmacogenet Genomics."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003088-200746040-00002","article-title":"The clinical pharmacokinetics of escitalopram","volume":"46","author":"Rao","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bcp.12348","article-title":"Citalopram and escitalopram plasma drug and metabolite concentrations: genome\u2010wide associations","volume":"78","author":"Ji","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FPC.0b013e32834d4962","article-title":"PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19","volume":"22","author":"Scott","year":"2012","journal-title":"Pharmacogenet Genomics."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0022-3565(24)36462-6","article-title":"Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes","volume":"280","author":"Kobayashi","year":"1997","journal-title":"J Pharmacol Exp Ther."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008571-199702000-00001","article-title":"Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes","volume":"7","author":"Rochat","year":"1997","journal-title":"Pharmacogenetics."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000028333","article-title":"Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes","volume":"59","author":"Olesen","year":"1999","journal-title":"Pharmacology."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/FPC.0b013e32832e0e97","article-title":"Cytochrome P450 2D6","volume":"19","author":"Owen","year":"2009","journal-title":"Pharmacogenet Genomics."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","article-title":"Inheritance and drug response","volume":"348","author":"Weinshilboum","year":"2003","journal-title":"N Engl J Med."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.clpt.6100291","article-title":"Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients","volume":"83","author":"Rudberg","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/FTD.0000000000000506","article-title":"Effects of cytochrome P450 (CYP) 2C19 genotypes on steady-state plasma concentrations of escitalopram and its desmethyl metabolite in Japanese patients with depression","volume":"40","author":"Tsuchimine","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2125.2003.01874.x","article-title":"Metabolism of citalopram enantiomers in CYP2C19\/CYP2D6 phenotyped panels of healthy Swedes","volume":"56","author":"Herrlin","year":"2003","journal-title":"Br J Clin Pharmacol."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/01.ftd.0000189899.23931.76","article-title":"Heterozygous mutation in CYP2C19 significantly increases the concentration\/dose ratio of racemic citalopram and escitalopram (S-citalopram)","volume":"28","author":"Rudberg","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881111414451","article-title":"CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP","volume":"26","author":"Huezo-Diaz","year":"2012","journal-title":"J Psychopharmacol."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1124\/dmd.109.029355","article-title":"Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopramin vitro","volume":"37","author":"Rudberg","year":"2009","journal-title":"Drug Metab Dispos."},{"key":"R20-20250603","first-page":"1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram","volume":"29","author":"Von Moltke","year":"2001","journal-title":"Drug Metab Dispos."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1553-2712.1997.tb03793.x","article-title":"Statistical methodology: III. Receiver operating characteristic (ROC) curves","volume":"4","author":"Grzybowski","year":"1997","journal-title":"Acad Emerg Med."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00007691-199302000-00002","article-title":"Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms","volume":"15","author":"Sindrup","year":"1993","journal-title":"Ther Drug Monit."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40262-014-0162-1","article-title":"Impact of cytochrome P450 2C19 polymorphisms on citalopram\/escitalopram exposure: a systematic review and meta-analysis","volume":"53","author":"Chang","year":"2014","journal-title":"Clin Pharmacokinet."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00702-014-1300-5","article-title":"Clinical applications of CYP genotyping in psychiatry","volume":"122","author":"Spina","year":"2014","journal-title":"J Neural Transm (Vienna)."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/FTD.0000000000000101","article-title":"Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline","volume":"37","author":"Gjestad","year":"2015","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000991","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:16:44Z","timestamp":1748971004000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000991","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"2022-02-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}